TerminatedNCT05109195
A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant
Observational studyAges 18–74United Kingdom + United StatesDepression
Understand this study
Who could participate?
Listed age limits: 18 years to 74 years.
- Listed locations
- San Francisco and 3 more locationsSee all locations and recruitment
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 26, 2021
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 7
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Observational
- Intervention type
- OTHER
- Study phase
- Not clearly listed
- Locations
- United States, United Kingdom
- Age range
- From 18 Years to 74 Years
- Official registry ID
- NCT05109195
- Official title
Show the full official title
A Prospective, Observational Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake /Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant as a Control Arm for the Safety Assessments in the Seltorexant Phase 3 Program
Recruitment & locations
TerminatedSan Francisco, United States · Boston, United States · Pittsburgh, United States
1 more locations
- Oxford, United Kingdom
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Who can participate?
Listed age limits: 18 years to 74 years.
Is this study still recruiting?
The registry lists this study as terminated.
